Noninvasive Diagnosis of Melanoma Uses Adhesive Tape and Genetic Testing

2011-02-13 16:02

EGIR Sampler™ device

Early detection and treatment of melanoma is important for optimal clinical outcome. Excisional biopsy of pigmented lesions deemed suspicious for the disease is the current method for diagnosis. The vast majority of such lesions biopsied are benign.

A noninvasive genomic test for melanoma has been developed by DermTech International which relies on a patented technology known as Epidermal Genetic Information Retrieval (EGIR) allows the collection of RNA from suspicious skin lesions before biopsies were performed using a special adhesive strip.

William Wachsman, MD, PhD and colleagues conducted a study to determine the accuracy of the adhesive tape using the EGIR technology. The results are reported in the British Journal of Dermatology included 202 lesion samples that were taped over the course of a year.

The researchers harvested skin overlying pigmented lesions clinically suspicious for melanoma using EGIR. RNA isolated from the tapes was amplified and gene expression profiled. All lesions were removed for histopathologic evaluation.

Earlier research identified 312 genes that are specific to melanomas, and the analysis included subset of 17 of these.

Upon testing with an independent dataset, this classifier discerns in situ and invasive melanomas from nevi with 100% sensitivity and 88% specificity, with an area under the curve for the receiver operating characteristic of >0.955.

The test has been patented, but has not sought FDA approval so it will be a few years before the average doctor has access to this noninvasive technique for diagnosing melanoma.


Subscribe to EmaxHealth on YouTube